Historical Valuation
Moleculin Biotech Inc (MBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.49. The fair price of Moleculin Biotech Inc (MBRX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.98
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Moleculin Biotech Inc (MBRX) has a current Price-to-Book (P/B) ratio of -0.27. Compared to its 3-year average P/B ratio of 16.85 , the current P/B ratio is approximately -101.58% higher. Relative to its 5-year average P/B ratio of 10.45, the current P/B ratio is about -102.55% higher. Moleculin Biotech Inc (MBRX) has a Forward Free Cash Flow (FCF) yield of approximately -201.32%. Compared to its 3-year average FCF yield of -225.14%, the current FCF yield is approximately -10.58% lower. Relative to its 5-year average FCF yield of -149.71% , the current FCF yield is about 34.47% lower.
P/B
Median3y
16.85
Median5y
10.45
FCF Yield
Median3y
-225.14
Median5y
-149.71
Competitors Valuation Multiple
AI Analysis for MBRX
The average P/S ratio for MBRX competitors is 0.89, providing a benchmark for relative valuation. Moleculin Biotech Inc Corp (MBRX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MBRX
1Y
3Y
5Y
Market capitalization of MBRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MBRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MBRX currently overvalued or undervalued?
Moleculin Biotech Inc (MBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.49. The fair price of Moleculin Biotech Inc (MBRX) is between to according to relative valuation methord.
What is Moleculin Biotech Inc (MBRX) fair value?
MBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Moleculin Biotech Inc (MBRX) is between to according to relative valuation methord.
How does MBRX's valuation metrics compare to the industry average?
The average P/S ratio for MBRX's competitors is 0.89, providing a benchmark for relative valuation. Moleculin Biotech Inc Corp (MBRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Moleculin Biotech Inc (MBRX) as of Jan 11 2026?
As of Jan 11 2026, Moleculin Biotech Inc (MBRX) has a P/B ratio of -0.27. This indicates that the market values MBRX at -0.27 times its book value.
What is the current FCF Yield for Moleculin Biotech Inc (MBRX) as of Jan 11 2026?
As of Jan 11 2026, Moleculin Biotech Inc (MBRX) has a FCF Yield of -201.32%. This means that for every dollar of Moleculin Biotech Inc’s market capitalization, the company generates -201.32 cents in free cash flow.
What is the current Forward P/E ratio for Moleculin Biotech Inc (MBRX) as of Jan 11 2026?
As of Jan 11 2026, Moleculin Biotech Inc (MBRX) has a Forward P/E ratio of -0.23. This means the market is willing to pay $-0.23 for every dollar of Moleculin Biotech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Moleculin Biotech Inc (MBRX) as of Jan 11 2026?
As of Jan 11 2026, Moleculin Biotech Inc (MBRX) has a Forward P/S ratio of 0.00. This means the market is valuing MBRX at $0.00 for every dollar of expected revenue over the next 12 months.